Loading…
Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting
Introduction Pharmacogenetics, in hand with precision medicine in oncology, represents an opportunity to holistically tailor a patient’s treatment regimen using both somatic and germline variants to improve efficacy and decrease toxicity. Colorectal cancer patients represent a population with freque...
Saved in:
| Published in: | Journal of oncology pharmacy practice 2022-06, Vol.28 (4), p.842-849 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c368t-61892cadb906d367f066ef8760ba0dad0072bd3a011be7342bdf244292f95fdd3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c368t-61892cadb906d367f066ef8760ba0dad0072bd3a011be7342bdf244292f95fdd3 |
| container_end_page | 849 |
| container_issue | 4 |
| container_start_page | 842 |
| container_title | Journal of oncology pharmacy practice |
| container_volume | 28 |
| creator | Luczak, Tiana S Schillo, Paul J Renier, Colleen M Waring, Stephen C Friday, Bret B |
| description | Introduction
Pharmacogenetics, in hand with precision medicine in oncology, represents an opportunity to holistically tailor a patient’s treatment regimen using both somatic and germline variants to improve efficacy and decrease toxicity. Colorectal cancer patients represent a population with frequent use of fluoropyrimidine and irinotecan and are an ideal opportunity for implementation of preemptive pharmacogenetics as evidence supports pharmacogenetic testing for DPYD and UGT1A1 to reduce fluoropyrimidine and irinotecan toxicities.
Methods
This was a single arm proof-of-concept study at a large community-based health system. Participants provided samples for pharmacogenetic testing via an external vendor prior to chemotherapy initiation and an oncology pharmacist was responsible for pharmacogenetic interpretation and pharmacogenetic-guided therapeutic recommendation to the treating provider.
Results
A total of 24 (60%) participants had a UGT1A1 variant. All participants (100%) were DPYD*1/*1. Results were available and interpreted for 29/40 (72.5%) participants prior to scheduled chemotherapy initiation (p value |
| doi_str_mv | 10.1177/10781552211005529 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2513243065</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_10781552211005529</sage_id><sourcerecordid>2513243065</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-61892cadb906d367f066ef8760ba0dad0072bd3a011be7342bdf244292f95fdd3</originalsourceid><addsrcrecordid>eNp1kU1P3DAQhq0KVBboD-ilssSllyxjO7GTI1qVD2klLiBxixxnshglTmo7VPvv62VpkUCcxpafeWbkl5DvDJaMKXXOQJWsKDhnDCDV6gtZsFypDCr-cJDO6T3bAUfkOIQnACgVL7-SIyHKQuQKFiRcog62sb2NWzp2dPKIwxTtM9LpUftBm3GDDqM1NGKI1m2oddSM_ejRRN1To51BTycdLboY6B8bHxOhEzMMs3vRuh2_2dKAcWc4JYed7gN-e60n5P7y193qOlvfXt2sLtaZEbKMmWRlxY1umwpkK6TqQErsSiWh0dDqFkDxphUaGGtQiTxdOp7nvOJdVXRtK07Iz7138uPvOW1fDzYY7HvtcJxDzQsmeC5AFgk9e4c-jbN3abuay0Km_1S8ShTbU8aPIXjs6snbQfttzaDeJVJ_SCT1_Hg1z82A7f-OfxEkYLkHgt7g29jPjX8BhWiU-g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2656092729</pqid></control><display><type>article</type><title>Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting</title><source>Sage Journals Online</source><creator>Luczak, Tiana S ; Schillo, Paul J ; Renier, Colleen M ; Waring, Stephen C ; Friday, Bret B</creator><creatorcontrib>Luczak, Tiana S ; Schillo, Paul J ; Renier, Colleen M ; Waring, Stephen C ; Friday, Bret B</creatorcontrib><description>Introduction
Pharmacogenetics, in hand with precision medicine in oncology, represents an opportunity to holistically tailor a patient’s treatment regimen using both somatic and germline variants to improve efficacy and decrease toxicity. Colorectal cancer patients represent a population with frequent use of fluoropyrimidine and irinotecan and are an ideal opportunity for implementation of preemptive pharmacogenetics as evidence supports pharmacogenetic testing for DPYD and UGT1A1 to reduce fluoropyrimidine and irinotecan toxicities.
Methods
This was a single arm proof-of-concept study at a large community-based health system. Participants provided samples for pharmacogenetic testing via an external vendor prior to chemotherapy initiation and an oncology pharmacist was responsible for pharmacogenetic interpretation and pharmacogenetic-guided therapeutic recommendation to the treating provider.
Results
A total of 24 (60%) participants had a UGT1A1 variant. All participants (100%) were DPYD*1/*1. Results were available and interpreted for 29/40 (72.5%) participants prior to scheduled chemotherapy initiation (p value <0.014). Of the participants whose results were available in 5 weekdays or less (n = 23), 20 (87%) were communicated with the treating provider prior to scheduled chemotherapy administration. A total turnaround time of 5 days or less was significantly associated with PGx feasibility in a community-based oncology clinic (p = 0.03).
Conclusions
In conclusion, we were able to show that implementation of preemptive pharmacogenetic testing into a community oncology clinic with results interpretation available prior to scheduled initiation of chemotherapy was feasible. As pharmacogenetic testing in oncology expands, pharmacists should be prepared to optimize supportive medication regimens as well as chemotherapy with pharmacogenetic results.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/10781552211005529</identifier><identifier>PMID: 33853470</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Chemotherapy ; Colorectal cancer ; Colorectal carcinoma ; Colorectal Neoplasms - drug therapy ; Colorectal Neoplasms - genetics ; Feasibility Studies ; Humans ; Irinotecan ; Irinotecan - therapeutic use ; Oncology ; Patients ; Pharmacists ; Pharmacogenetics ; Pharmacogenomic Testing ; Precision medicine ; Toxicity</subject><ispartof>Journal of oncology pharmacy practice, 2022-06, Vol.28 (4), p.842-849</ispartof><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-61892cadb906d367f066ef8760ba0dad0072bd3a011be7342bdf244292f95fdd3</citedby><cites>FETCH-LOGICAL-c368t-61892cadb906d367f066ef8760ba0dad0072bd3a011be7342bdf244292f95fdd3</cites><orcidid>0000-0001-9398-7155</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925,79364</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33853470$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Luczak, Tiana S</creatorcontrib><creatorcontrib>Schillo, Paul J</creatorcontrib><creatorcontrib>Renier, Colleen M</creatorcontrib><creatorcontrib>Waring, Stephen C</creatorcontrib><creatorcontrib>Friday, Bret B</creatorcontrib><title>Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting</title><title>Journal of oncology pharmacy practice</title><addtitle>J Oncol Pharm Pract</addtitle><description>Introduction
Pharmacogenetics, in hand with precision medicine in oncology, represents an opportunity to holistically tailor a patient’s treatment regimen using both somatic and germline variants to improve efficacy and decrease toxicity. Colorectal cancer patients represent a population with frequent use of fluoropyrimidine and irinotecan and are an ideal opportunity for implementation of preemptive pharmacogenetics as evidence supports pharmacogenetic testing for DPYD and UGT1A1 to reduce fluoropyrimidine and irinotecan toxicities.
Methods
This was a single arm proof-of-concept study at a large community-based health system. Participants provided samples for pharmacogenetic testing via an external vendor prior to chemotherapy initiation and an oncology pharmacist was responsible for pharmacogenetic interpretation and pharmacogenetic-guided therapeutic recommendation to the treating provider.
Results
A total of 24 (60%) participants had a UGT1A1 variant. All participants (100%) were DPYD*1/*1. Results were available and interpreted for 29/40 (72.5%) participants prior to scheduled chemotherapy initiation (p value <0.014). Of the participants whose results were available in 5 weekdays or less (n = 23), 20 (87%) were communicated with the treating provider prior to scheduled chemotherapy administration. A total turnaround time of 5 days or less was significantly associated with PGx feasibility in a community-based oncology clinic (p = 0.03).
Conclusions
In conclusion, we were able to show that implementation of preemptive pharmacogenetic testing into a community oncology clinic with results interpretation available prior to scheduled initiation of chemotherapy was feasible. As pharmacogenetic testing in oncology expands, pharmacists should be prepared to optimize supportive medication regimens as well as chemotherapy with pharmacogenetic results.</description><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Colorectal Neoplasms - drug therapy</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Feasibility Studies</subject><subject>Humans</subject><subject>Irinotecan</subject><subject>Irinotecan - therapeutic use</subject><subject>Oncology</subject><subject>Patients</subject><subject>Pharmacists</subject><subject>Pharmacogenetics</subject><subject>Pharmacogenomic Testing</subject><subject>Precision medicine</subject><subject>Toxicity</subject><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp1kU1P3DAQhq0KVBboD-ilssSllyxjO7GTI1qVD2klLiBxixxnshglTmo7VPvv62VpkUCcxpafeWbkl5DvDJaMKXXOQJWsKDhnDCDV6gtZsFypDCr-cJDO6T3bAUfkOIQnACgVL7-SIyHKQuQKFiRcog62sb2NWzp2dPKIwxTtM9LpUftBm3GDDqM1NGKI1m2oddSM_ejRRN1To51BTycdLboY6B8bHxOhEzMMs3vRuh2_2dKAcWc4JYed7gN-e60n5P7y193qOlvfXt2sLtaZEbKMmWRlxY1umwpkK6TqQErsSiWh0dDqFkDxphUaGGtQiTxdOp7nvOJdVXRtK07Iz7138uPvOW1fDzYY7HvtcJxDzQsmeC5AFgk9e4c-jbN3abuay0Km_1S8ShTbU8aPIXjs6snbQfttzaDeJVJ_SCT1_Hg1z82A7f-OfxEkYLkHgt7g29jPjX8BhWiU-g</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Luczak, Tiana S</creator><creator>Schillo, Paul J</creator><creator>Renier, Colleen M</creator><creator>Waring, Stephen C</creator><creator>Friday, Bret B</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9398-7155</orcidid></search><sort><creationdate>20220601</creationdate><title>Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting</title><author>Luczak, Tiana S ; Schillo, Paul J ; Renier, Colleen M ; Waring, Stephen C ; Friday, Bret B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-61892cadb906d367f066ef8760ba0dad0072bd3a011be7342bdf244292f95fdd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Colorectal Neoplasms - drug therapy</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Feasibility Studies</topic><topic>Humans</topic><topic>Irinotecan</topic><topic>Irinotecan - therapeutic use</topic><topic>Oncology</topic><topic>Patients</topic><topic>Pharmacists</topic><topic>Pharmacogenetics</topic><topic>Pharmacogenomic Testing</topic><topic>Precision medicine</topic><topic>Toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luczak, Tiana S</creatorcontrib><creatorcontrib>Schillo, Paul J</creatorcontrib><creatorcontrib>Renier, Colleen M</creatorcontrib><creatorcontrib>Waring, Stephen C</creatorcontrib><creatorcontrib>Friday, Bret B</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luczak, Tiana S</au><au>Schillo, Paul J</au><au>Renier, Colleen M</au><au>Waring, Stephen C</au><au>Friday, Bret B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><addtitle>J Oncol Pharm Pract</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>28</volume><issue>4</issue><spage>842</spage><epage>849</epage><pages>842-849</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Introduction
Pharmacogenetics, in hand with precision medicine in oncology, represents an opportunity to holistically tailor a patient’s treatment regimen using both somatic and germline variants to improve efficacy and decrease toxicity. Colorectal cancer patients represent a population with frequent use of fluoropyrimidine and irinotecan and are an ideal opportunity for implementation of preemptive pharmacogenetics as evidence supports pharmacogenetic testing for DPYD and UGT1A1 to reduce fluoropyrimidine and irinotecan toxicities.
Methods
This was a single arm proof-of-concept study at a large community-based health system. Participants provided samples for pharmacogenetic testing via an external vendor prior to chemotherapy initiation and an oncology pharmacist was responsible for pharmacogenetic interpretation and pharmacogenetic-guided therapeutic recommendation to the treating provider.
Results
A total of 24 (60%) participants had a UGT1A1 variant. All participants (100%) were DPYD*1/*1. Results were available and interpreted for 29/40 (72.5%) participants prior to scheduled chemotherapy initiation (p value <0.014). Of the participants whose results were available in 5 weekdays or less (n = 23), 20 (87%) were communicated with the treating provider prior to scheduled chemotherapy administration. A total turnaround time of 5 days or less was significantly associated with PGx feasibility in a community-based oncology clinic (p = 0.03).
Conclusions
In conclusion, we were able to show that implementation of preemptive pharmacogenetic testing into a community oncology clinic with results interpretation available prior to scheduled initiation of chemotherapy was feasible. As pharmacogenetic testing in oncology expands, pharmacists should be prepared to optimize supportive medication regimens as well as chemotherapy with pharmacogenetic results.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>33853470</pmid><doi>10.1177/10781552211005529</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9398-7155</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-1552 |
| ispartof | Journal of oncology pharmacy practice, 2022-06, Vol.28 (4), p.842-849 |
| issn | 1078-1552 1477-092X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2513243065 |
| source | Sage Journals Online |
| subjects | Chemotherapy Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Feasibility Studies Humans Irinotecan Irinotecan - therapeutic use Oncology Patients Pharmacists Pharmacogenetics Pharmacogenomic Testing Precision medicine Toxicity |
| title | Feasibility of preemptive pharmacogenetic testing in colorectal cancer patients within a community oncology setting |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T14%3A26%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Feasibility%20of%20preemptive%20pharmacogenetic%20testing%20in%20colorectal%20cancer%20patients%20within%20a%20community%20oncology%20setting&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Luczak,%20Tiana%20S&rft.date=2022-06-01&rft.volume=28&rft.issue=4&rft.spage=842&rft.epage=849&rft.pages=842-849&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/10781552211005529&rft_dat=%3Cproquest_cross%3E2513243065%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c368t-61892cadb906d367f066ef8760ba0dad0072bd3a011be7342bdf244292f95fdd3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2656092729&rft_id=info:pmid/33853470&rft_sage_id=10.1177_10781552211005529&rfr_iscdi=true |